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SUMMARY: 41 
This article describes a step-by-step protocol to set up an ex vivo porcine model of bacterial 42 
keratitis. Pseudomonas aeruginosa is used as a prototypic organism. This innovative model 43 
mimics in vivo infection as bacterial proliferation is dependent on the ability of the bacterium 44 
to damage corneal tissue.  45 
 46 
ABSTRACT: 47 
Manuscript Click here to access/download;Manuscript;61156_R1.docx
When developing novel antimicrobials, the success of animal trials is dependent on accurate 48 
extrapolation of antimicrobial efficacy from in vitro tests to animal infections in vivo. The 49 
existing in vitro tests typically overestimate antimicrobial efficacy as the presence of host 50 
tissue as a diffusion barrier is not accounted for. To overcome this bottleneck, we have 51 
developed an ex vivo porcine corneal model of bacterial keratitis using Pseudomonas 52 
aeruginosa as a prototypic organism. This article describes the preparation of the porcine 53 
cornea and protocol for establishment of the infection. Bespoke glass molds enable 54 
straightforward setup of the cornea for infection studies. The model mimics in vivo infection 55 
as bacterial proliferation is dependent on the ability of the bacterium to damage corneal 56 
tissue. Establishment of infection is verified as an increase in the number of colony forming 57 
units assessed via viable plate counts. The results demonstrate that infection can be 58 
established in a highly reproducible fashion in the ex vivo corneas using the method described 59 
here. The model can be extended in the future to mimic keratitis caused by microorganisms 60 
other than P. aeruginosa. The ultimate aim of the model is to investigate the effect of 61 
antimicrobial chemotherapy on the progress of bacterial infection in a scenario more 62 
representative of in vivo infections. In so doing, the model described here will reduce the use 63 
of animals for testing, improve success rates in clinical trials and ultimately enable rapid 64 
translation of novel antimicrobials to the clinic. 65 
 66 
INTRODUCTION 67 
Corneal infections are important causes of blindness and occur in epidemic proportions in 68 
low- and mid-income countries. The etiology of the disease varies from region to region but 69 
bacteria account for a large majority of these cases. Pseudomonas aeruginosa is an important 70 
pathogen that causes a rapidly progressive disease. In many cases, patients are left with 71 
stromal scarring, irregular astigmatism, require transplant or in the worst case scenario, lose 72 
an eye1,2.  73 
 74 
Bacterial keratitis caused by P. aeruginosa is a difficult eye infection to treat particularly due 75 
to the increasing emergence of antimicrobial resistant strains of P. aeruginosa. Within the last 76 
decade, it has become apparent that testing and developing new treatments for corneal 77 
infections, in general, and those caused by Pseudomonas sp., in particular, are essential to 78 
combat the current trend in antibiotic resistance3.  79 
 80 
For testing the efficacy of new treatments for corneal infections, conventional in vitro 81 
microbiological methods are a poor surrogate due to the difference in bacterial physiology 82 
during laboratory culture and during infections in vivo as well as due to the lack of the host 83 
interface4,5. In vivo animal models, however, are expensive, time-consuming, can only deliver 84 
a small number of replicates and raise concerns about animal welfare.  85 
 86 
In this article, we demonstrate a simple and reproducible organotypic ex vivo porcine model 87 
of keratitis that can be used to test various treatments for acute and chronic infections. We 88 
have used P. aeruginosa for this experiment but the model also works well with other 89 
bacteria, and organisms such as fungi and yeast which cause keratitis. 90 
 91 
PROTOCOL: 92 
Albino laboratory rabbits were sacrificed in the laboratory for other planned experimental 93 
work under home office approved protocols. The eyes were not required for experimental 94 
use in those studies so they were used for this protocol. 95 
 96 
1. Sterilization  97 
 98 
1.1. CRITICAL STEP: Disinfect all forceps and scissors by soaking for 1 h in 5% (v/v) solution 99 
of Distel in distilled water, clean with a brush, rinse with tap water and sterilize in an oven at 100 
185 °C for a minimum of 2 h.  101 
 102 
1.2. Sterilize all other glassware and reagents by autoclaving at 121 °C for 15 minutes or 103 
prepare reagents ;IIﾗヴSｷﾐｪ デﾗ デｴW ﾏ;ﾐ┌a;Iデ┌ヴWヴげゲ ｷﾐゲデヴ┌Iデｷﾗﾐゲ. Carry out the following 104 
procedures in a class II microbiology safety cabinet. 105 
 106 
2. Sample collection  107 
 108 
2.1. Collection of porcine eyes  109 
 110 
2.1.1. Use large white landrace sows, a cross with a Hampshire boar. The age of the pigs was 111 
between 21 to 23 weeks when slaughtered in a local abattoir for food consumption. Stun the 112 
animals with an electric current and enucleate the eyes 2 h later in the abattoir.  113 
 114 
2.1.2. CRITICAL STEP: Once enucleated, transfer the eyes to the lab in a sterile phosphate 115 
buffered saline (PBS) solution to prevent them from drying out and process them immediately 116 
upon arrival. 117 
 118 
2.2. Collection of rabbit eyes 119 
 120 
2.2.1. Excise the corneas and send to the lab in sterile PBS. 121 
 122 
3. Preparation of the corneoscleral button 123 
 124 
3.1. Use sterile forceps to hold the tissue surrounding the eyeball and transfer it to a Petri 125 
dish. Remove the conjunctiva and muscle tissue around the eyeball on a Petri dish using 126 
scalpel blade no. 15 and forceps.  127 
 128 
3.2. Gently lift the eyeball while holding the optic nerve with forceps and transfer to a 0.5 129 
L jar filled with sterile PBS. 130 
 131 
3.3. Once all eyes are cleared of surrounding tissue, move them using sterile forceps to 132 
another 0.5 L jar filled with 3% (v/v) povidone iodine in PBS and leave for 1 min. 133 
 134 
3.4. Transfer eyeballs to another 0.5 L jar with sterile PBS. 135 
 136 
3.5. Use forceps to hold the eye still on a Petri dish and make a cut near the cornea with a 137 
scalpel blade no 10A.  138 
 139 
3.6. CRITICAL STEP: Hold the edge of the cut and use scissors to excise the cornea leaving 140 
about 3 mm of sclera surrounding the cornea. Ensure the sharp end of scissors does not pierce 141 
the iris or the choroidal tissue and is in the supra-choroidal space. 142 
 143 
3.7. Hold the corneoscleral button with forceps and use another pair of pointed end 144 
forceps to gently separate the uveal tissue.  145 
 146 
3.8. Lift the corneoscleral button from remaining globe and briefly rinse it in 1.5% (v/v) 147 
povidone iodine solution in PBS in a 12 well plate.  148 
 149 
3.9. Place the corneoscleral button into another 12 well plate filled with sterile PBS. 150 
 151 
3.10. After processing all eyes (do no more than 40 eyes in one batch), place each 152 
corneoscleral button to an individual Petri dish (34 mm diameter) epithelial side up and pour 153 
in 3 mL of culture medium pre-warmed to 37 °C. 154 
 155 
NOTE: The composition of the culture medium is as follows: D┌ﾉHWIIﾗげゲ ﾏﾗSｷaｷWS E;ｪﾉWげゲ 156 
medium (DMEM)ぎ H;ﾏげゲ ぷヱぎヱへ ゲ┌ヮヮﾉWﾏWﾐデWS ┘ｷデｴ ヵ ´ｪびmL-1 insulin and 10 ngびmL-1 epidermal 157 
growth factor (EGF), 10% (v/v) foetal calf serum (FCS), 100 UびmL-1 penicillin, 100 UびmL-1 158 
ゲデヴWヮデﾗﾏ┞Iｷﾐ ;ﾐS ヲくヵ ´ｪびmL-1 amphotericin B. As an optional step, the medium can be 159 
supplemented with 50 gびL-1 dextran to prevent swelling of the excised cornea during the 160 
further incubation steps. 161 
 162 
3.11. Incubate at 37 °C in a humidified tissue culture incubator. 163 
 164 
4. Maintenance of the corneoscleral buttons 165 
 166 
4.1. After 24 hours, use aseptic technique to remove media and replace with 3 mL of fresh 167 
pre-warmed culture media containing antibiotics. Keep the corneoscleral buttons in media 168 
with antibiotics for 48 h to disinfect the corneas. Incubate at 37 °C in a humidified tissue 169 
culture incubator. 170 
 171 
4.2. CRITICAL STEP: After 48 hours, remove the media and rinse corneas with 2 mL of PBS. 172 
Then keep the corneoscleral buttons in antibiotic-free media for a minimum of two or ideally 173 
three days before experimental infection, to remove residual antibiotics from the tissue.  174 
 175 
4.3. Incubate at 37 °C in a humidified tissue culture incubator. Change media at least one 176 
more time within these three days. Discard corneas if any turbidity develops in the antibiotic-177 
free medium. 178 
 179 
5. Preparation of an inoculum 180 
 181 
5.1. Pour 10 mL of LB broth into a 50 mL conical flask with a foam stopper. 182 
 183 
5.2. Transfer a colony of P. aeruginosa  strain PAO1 or strain PA14 from a fresh agar plate 184 
and incubate at 37 °C for 3-4 h until the bacteria are in mid-log phase. 185 
 186 
5.3. Transfer the culture of bacteria to a 50 mL tube and centrifuge at 3,000 x g for 5 min. 187 
Remove the supernatant and re-suspend the cell pellet in PBS. 188 
 189 
5.4. Repeat step 5.3 two more times to wash the cells. Re-suspend the cell pellet in PBS 190 
and adjust the optical density at 600 nm to approximately 0.6 using sterile PBS as a blank.  191 
 192 
6. Infecting the corneoscleral button 193 
 194 
6.1. Remove media from the Petri dish and rinse corneas twice with 1 mL of sterile PBS. 195 
 196 
6.2. Gently squeeze forceps while holding the cornea in-between. Use a 10A scalpel to 197 
make four cuts に two vertical, two horizontal - in the central section of the corneoscleral 198 
button through the epithelial layer to the underlying stroma. 199 
 200 
6.3. Place a sterile glass mold in a 6-well plate with the wide part up and place the cornea 201 
in the middle of the glass mold, epithelium side facing down. Make the cut right in the center 202 
of the bottom part of the glass mold. 203 
 204 
6.4. CRITICAL STEP: Pour 1 mL of 1% (w/v) low melting point agar dissolved in DMEM to fill 205 
the glass mold with cornea completely. 206 
 207 
6.5. Allow the agar to set and then invert the glass mold so that the corneal epithelium is 208 
facing upwards. 209 
 210 
6.6. Pipette 15 ´L of the bacterial culture with OD600nm = 0.6 (for P. aeruginosa this equates 211 
to approximately 1 x 107 colony forming units (CFU) ｷﾐ ヱヵ ´L) directly into a cut area and then 212 
add 85 ´L of PBS to the top to keep the corneal epithelium moist. 213 
 214 
6.7. Add 1 mL of DMEM without antibiotics to the bottom of each well with the glass mold. 215 
Incubate the 6-well plate with the infected corneoscleral buttons in a humidified incubator at 216 
37 °C with 5% CO2 for up to 24 h.  217 
 218 
6.8.  Set up uninfected control cornea alongside every experiment. To set up uninfected 219 
Iﾗﾐデヴﾗﾉが ヴWヮﾉ;IW デｴW ヱヵ ´L ﾗa H;IデWヴｷ;ﾉ I┌ﾉデ┌ヴW in step 6.6 with sterile PBS. 220 
 221 
7. Homogenization of the cornea to harvest the bacteria 222 
 223 
7.1. Discard the DMEM medium from the bottom of the 6 well plate and add 1 mL of sterile 224 
PBS to rinse the bottom of the well.  225 
 226 
7.2. Remove PBS gently by pipetting without touching the central part of the corneoscleral 227 
button. Remove the glass ring using sterile forceps and place it in the 5% Distel. 228 
 229 
7.3. Gently rinse the top of the corneoscleral button with 1 mL of PBS twice [optional].  230 
 231 
7.4. Hold the edge of the corneoscleral button with fine tip forceps and detach it from the 232 
agar underneath. 233 
 234 
7.5. Remove the corneoscleral button and place on a sterile Petri dish. Remove the 235 
remaining sclera using a scalpel and then transfer the cornea to a 50 mL tube filled with ice 236 
cold 1-2 mL of PBS.  237 
 238 
7.6. Use a fine tip homogenizer to sheer the top of the infected cornea. The tissue does 239 
not have to be completely liquidized. The homogenizer helps to detach bacteria from the 240 
corneal epithelium and the cut area. 241 
 242 
7.7. Vortex the cornea in PBS for a few seconds to mix the contents. 243 
 244 
7.8. Add 20 ´L of the homogenate to 180 ´L of PBS and perform serial dilutions in a 96 well 245 
plate. 246 
 247 
7.9. Serially dilute the suspension to 10-4 and 10-5 dilution and pipette 10 ´L of the diluted 248 
homogenate with bacteria onto a blood agar plate. Incubate the plate for 8 hours and count 249 
the number of CFU. When testing the effect of antimicrobials, the appropriate dilution factor 250 
must be arrived at experimentally. 251 
 252 
7.10. In every experiment, homogenize one cornea immediately after infection and perform 253 
viable plate count to ensure that the infective dose is approximately 1 x 107 CFU per cornea. 254 
 255 
REPRESENTATIVE RESULTS 256 
The design of the glass molds are an innovative and original idea, the use of which allowed us 257 
to set up the model in a consistent fashion with minimal/no issues with contamination. The 258 
molds were prepared by a glass blower at the University of Sheffield based on a design (Figure 259 
1A). The experimental setup maintains the convex shape of the cornea and holds bacteria on 260 
the top of the epithelium where infection takes place (Figure 1B).  261 
 262 
Porcine corneas usually swell after few days in medium. This is normal and we found that 263 
there was no significant difference between corneas with and without addition of dextran, 264 
which is usually added to prevent swelling of the cornea (Figure 1H). The corneas are typically 265 
wounded to help the bacteria penetrate the epithelium. Although there was no significant 266 
difference in the progress of infection between wounded (cut) and unwounded (uncut) 267 
corneas, we noticed more variations between replicates in uncut corneas (Figure 1C). 268 
Washing the corneas twice with PBS removes excess bacteria that did not attach to the 269 
epithelium. There was a significant difference in CFU between washed and unwashed porcine 270 
corneas infected with P. aeruginosa PAO1 for 24 hours (Figure 1D). There was no significant 271 
difference in CFU counts between porcine and rabbit corneas infected with PA14 and PAO1 272 
(Figure 1E,1F). The results for both models were reproducible. After 24 hours, the cornea 273 
infected with either Pseudomonas strain always develop opacity and the cut area becomes 274 
more visible and open in comparison to the uninfected cornea (Figure 1G).  275 
 276 
Figure 1: Ex vivo cornea infected with Pseudomonas aeruginosa. (A) Schematic picture of a 277 
glass mold used for maintaining the shape of the cornea and facilitating the introduction of 278 
bacteria and treatments. The thickness of the glass molds is 1.5 mm and is the same as the 279 
thickness of test tubes made from borosilicate glass. (B) Schematic picture of the 280 
experimental set up. (C) Testing the effect of wounding on the final CFU count after 281 
homogenization. Uncut (n = 16) and cut (n = 28) corneas were infected with P. aeruginosa 282 
PAO1 and P. aeruginosa PA14 for 24 hours. The corneas were washed with 1 mL of PBS before 283 
homogenization. Error bars indicate standard deviation. (D) Testing the effect of washing 284 
corneas with 2 x 1 mL of PBS (n = 6) and not washing (n = 6) on the final CFU count after 285 
infection with P. aeruginosa PAO1 for 24 hours. Error bars indicate standard deviation. (E) 286 
Final CFU count in porcine corneas infected with P. aeruginosa PAO1 and P. aeruginosa PA14 287 
for 24 hours (n = 10). Corneas were washed and cut. Error bars indicate standard deviation. 288 
(F) Final CFU count in rabbit corneas infected with P. aeruginosa PAO1 and P. aeruginosa PA14 289 
for 24 hours (n = 6). Corneas were washed and cut. Error bars indicate standard deviation. (G) 290 
Pictures of ex vivo porcine corneas infected with P. aeruginosa PAO1 for 24 hours. The control 291 
was wounded but no bacteria were added. The infected corneas were wounded and 107 CFU 292 
were added to the cut side. No CFU were recovered from the control cornea. (H) Final CFU 293 
recovered after 24 hours of infection with P. aeruginosa PAO1 from corneas treated with 294 
dextran (n = 2) and those without dextran (n = 9). Corneas were washed and cut. Error bars 295 
indicate standard deviation. 296 
 297 
DISCUSSION: 298 
The main driver behind the development of this keratitis model using ex vivo porcine cornea 299 
is to provide researchers developing novel antimicrobials with a representative in vitro model 300 
to more accurately determine antimicrobial efficacy at the preclinical stages. This will provide 301 
researchers involved in developing new antimicrobials greater control over drug design and 302 
formulation at the pre-clinical stages, increase success at clinical trials, reduce use of animals 303 
by enabling targeted studies and result in faster translation of new antimicrobials to clinic. 304 
 305 
A number of studies have investigated the effect of infections on ex vivo corneas from various 306 
animals such as: rabbit6, dog7, goat8 and pigs9-11. Most of these studies focus on ways of 307 
establishing6 and visualizing an infection9 but so far there have only been a few publications 308 
focusing on drug testing and accurate quantification of bacteria6-8,12. 309 
 310 
The primary advantage of our model is the availability of the porcine corneas as part of the 311 
food chain. The use of ex vivo porcine corneas therefore aligns with the principle of 3Rs, which 312 
is to replace, refine and reduce the use of animals in research, whilst providing a 313 
representative model of the host interface. We have observed no issues with contamination 314 
of the corneal explants if the protocol is strictly followed. The glass molds are very easy, quick 315 
and straightforward to use without any requirement for specialized equipment. The narrow 316 
ring at the top makes the addition of a small quantity of a tested drug (100 µL) or bacteria 317 
convenient. The ring of the glass mold allows PBS with bacteria or a drug solution to be 318 
retained in the central part of the cornea and prevents the bacteria from getting underneath 319 
the cornea. The ring is easy to clean and sterilize, and allows the observation of the changes 320 
that occur on the top of the cornea during infection. Strains of fluorescently-tagged bacteria 321 
can be used to visualize infection or quantify the spread of infection in the tissue using 322 
fluorescent confocal microscopy. The whole corneas can be further processed for histology 323 
or electron microscopy imaging. 324 
 325 
The critical steps are marked in the protocol. Extra attention must be paid to these steps when 326 
carrying out the protocol to ensure successful infection. The most critical steps within the 327 
protocol are ensuring that the corneas are treated with sufficient antibiotics to prevent 328 
infection during preparation and then that the antibiotics are sufficiently eliminated before 329 
the introduction of the infective organism, in this case P. aeruginosa. When setting up the 330 
experiments using this protocol, in some instances, turbidity developed during incubation in 331 
the antibiotic-free medium. This turbidity was indicative of growth of microorganisms in the 332 
antibiotic-free medium. This might be due to incomplete treatment of the cornea using the 333 
antibiotics or due to contamination during handling. These corneas were not taken forward 334 
for further experiments and were discarded. Development of turbidity when incubating 335 
corneas in antibiotic-free medium was avoided by employing frequent sterilization runs in the 336 
incubator, using disposable pipette tips with a filter and taking adequate care when sterilizing 337 
the tools used for excising the cornea from the porcine eyes. Another critical step is when the 338 
corneas are placed in the glass mold prior to infection. The glass mold enables one to maintain 339 
the convex shape of the cornea. The convexity of the cornea is a challenge for retention of 340 
either the infective dose or the therapeutic agent on the surface of the cornea. Therefore, it 341 
is essential to ensure the presence of adequate seal between the cornea and the glass mold. 342 
When there is adequate seal between the cornea and the glass mold, the ring structure above 343 
the mold creates a reservoir to retain either the infective dose or the therapeutic agent. An 344 
adequate seal is ensured by completely filling the wide section of the glass mold with DMEM 345 
agar up to the brim. 346 
 347 
As is the case with any model, there are limitations associated with the ex vivo porcine cornea 348 
model described. The model described herein does not mimic the composition, flow and 349 
replenishment of the tear film across the cornea. The mechanical action provided by blinking 350 
is also not incorporated into the model. There is agreement in the literature that tear film 351 
composition and dynamics, and blinking are important defense mechanisms that remove 352 
foreign particles and microorganisms from the eye13. Indeed, the model also lacks an immune 353 
response that is triggered during infection in vivo. It is likely that the progression of infection 354 
in vivo in the presence of these defense mechanisms is different to that observed in the ex 355 
vivo model described here. Despite these limitations, the ex vivo porcine corneal model is 356 
relevant for testing the effectiveness of existing and emerging antimicrobials for two main 357 
reasons: 1) the physiology of the bacteria in the ex vivo model mimics the in vivo conditions 358 
as bacterial proliferation is dependent on their ability to damage the corneal tissue, and 2) 359 
the model incorporates the three dimensional tissue as a diffusion barrier for therapeutics 360 
much like in the in vivo situation. Therefore, the ex vivo model is advantageous over 361 
conventional techniques for antimicrobial susceptibility testing. 362 
 363 
The ex vivo porcine cornea model described here can be also used for studying different 364 
strains of bacteria, fungi and yeast that cause keratitis. This ex vivo cornea model is 365 
reproducible and allows one to generate replicates within a short time unlike in vivo models. 366 
Instead of PBS, artificial tears or host immune defense cells can theoretically be added to 367 
mimic the live scenario. Corneas are obtained from the same breed of pigs and about 21-23 368 
weeks old when slaughtered. Therefore, there is less variability between replicates compared 369 
to those obtained from human cadavers. The concept of using a porcine ex vivo cornea model 370 
for biomedical applications has gained more popularity within the last few years because of 371 
its biological similarity to the human eye which makes this model easier to compare14. There 372 
is increased interest in using porcine corneas for transplantation15,16 or as a model for dry 373 
eye17 or wound healing18.  374 
 375 
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Revised Figure (.psd) Click here to access/download;Figure;Revised_Fig_1_psd.psd
Name of Material/Equipment Company Catalog Number Comments/Description
50 mL Falcon tube SLS 352070
Amphotericin B Sigma A2942
Cellstar 12 well plate Greiner Bio-One 665180
Dextran Sigma 31425-100mg-F
Distel Fisher Scientific 12899357
DMEM + glutamax SLS D0819
Dual Oven Incubator SLS OVe1020 Sterilising oven
Epidermal growth factor SLS E5036-200UG
F12 HAM Sigma N4888
Foetal calf serum 
Labtech 
International CA-115/500
Forceps Fisher Scientific 15307805
Handheld homogeniser 220 Fisher Scientific 15575809 Homogeniser
Heracell VIOS 160i Thermo Scientific 15373212  Tissue culture incubator
Heraeus Megafuge 16R VWR 521-2242 Centrifuge
Insulin, recombinant Human SLS 91077C-1G
LB agar Sigma L2897
Multitron Infors Not appplicable Bacterial incubator
PBS SLS P4417
Penicillin-Streptomycin SLS P0781
Petri dish Fisher Scientific 12664785




Safe 2020 Fisher Scientific 1284804 Class II microbiology safety cabinet
Scalpel blade number 15 Fisher Scientific O305
Scalpel Swann Morton Fisher Scientific 11849002
Table of Materials Click here to access/download;Table of
Materials;Revised_JoVE_Table_of_Materials.xlsx
AUTHORSげ RESPONSE TO EDITORIAL AND REVIEWERSげ COMMENTS 
Dear Editor, 
The authors would like to thank the editorial board and the reviewers for taking to time to review the 
manuscript and comment on it. The authors found the comments valuable and have made 
modifications to the original manuscript to incorporate the suggested changes. The quality of the 
ﾏ;ﾐ┌ゲIヴｷヮデ ｴ;ゲ ｷﾏヮヴﾗ┗WS ;ゲ ; ヴWゲ┌ﾉデく PﾉW;ゲW aｷﾐS HWﾉﾗ┘ デｴW ;┌デｴﾗヴゲげ ヴWゲヮﾗﾐゲWゲ デﾗ デｴW ゲヮWIｷaｷI IﾗﾏﾏWﾐデゲ 
raised. We trust the changes we have made are satisfactory and that the manuscript will be accepted 
for publication in JoVE. 





1. Please take this opportunity to thoroughly proofread the manuscript to ensure that there are no 
spelling or grammar issues. 
Response: This has been carried out.  
 
2. Please incﾉ┌SW ;ﾉﾉ ;┌デｴﾗヴゲげ Wﾏ;ｷﾉゲ ｷﾐ デｴW ﾏ;ﾐ┌ゲIヴｷヮデ ｷデゲWﾉaく  
Response: The email addresses of all authors has been added to the manuscript under a separate 
subsection titled emails.  
 
3. JoVE cannot publish manuscripts containing commercial language. This includes trademark symbols 
ふゥぶが ヴWｪｷゲデWヴWS ゲ┞ﾏHﾗﾉゲ ふイぶが ;ﾐS Iﾗﾏヮ;ﾐ┞ ﾐ;ﾏWゲ HWaﾗヴW ;ﾐ ｷﾐゲデヴ┌ﾏWﾐデ ﾗヴ ヴW;ｪWﾐデく PﾉW;ゲW ﾉｷﾏｷデ デｴW ┌ゲW 
of commercial language from your manuscript and use generic terms instead. All commercial products 
should be sufficiently referenced in the Table of Materials and Reagents. 
For example: Distel, Falcon, Lonza  
Response: All trademark and registered symbols have now been removed from the manuscript and 
from the Table of Materials and Reagents. 
 
Protocol: 
ヱく Fﾗヴ W;Iｴ ヮヴﾗデﾗIﾗﾉ ゲデWヮっゲ┌HゲデWヮが ヮﾉW;ゲW Wﾐゲ┌ヴW ┞ﾗ┌ ;ﾐゲ┘Wヴ デｴW さｴﾗ┘ざ ケ┌Wゲデｷﾗﾐが ｷくWくが ｴﾗ┘ ｷゲ デｴW ゲデWヮ 
performed? Alternatively, add references to published material specifying how to perform the 
protocol action. If revisions cause a step to have more than 2-3 actions and 4 sentences per step, 
please split into separate steps or substeps.  
Response: C;ヴW ｴ;ゲ HWWﾐ デ;ﾆWﾐ デﾗ Wﾐゲ┌ヴW デｴW さｴﾗ┘ざ ﾗa W;Iｴ ゲデWヮ ｷゲ Iﾗ┗WヴWSく “デWヮ Α ｷﾐ ヮ;ヴデ ン ｴ;ゲ HWWﾐ 
split in to two separate steps (Part 3 steps 7 and 8) in the revised manuscript to aid clarity. 
 
Specific Protocol steps: 
Rebuttal Letter Click here to access/download;Rebuttal Letter;Rebuttal
letter.docx
 
1. 3.3: This is a bit confusing- do you mean to leave the eyeball in PBS for 1 minute?  
Response: Yes, that is correct. The authors have modified the wording in step 3.3 to aid clarity. 
 
Figures: 
1. Figure 1: The text is generally hard to read, including in the original image file. 
Response: The font size of the text in the figures has been increased in the revised manuscript. 
ヲく Fｷｪ┌ヴW ヱAぎ けデｷ;ﾏWデWヴげ ｷゲ ; デ┞ヮﾗく  
Response: The typo has been corrected in the revised manuscript. 
 
Discussion: 
1. Please revise the Discussion to explicitly cover the following in detail in 3に6 paragraphs with 
citations: 
a) Critical steps within the protocol  
b) Any modifications and troubleshooting of the technique  
c) Any limitations of the technique 
Response: CヴｷデｷI;ﾉ ゲデWヮゲ ｴ;┗W HWWﾐ ｷSWﾐデｷaｷWS ｷﾐ デｴW ヮヴﾗデﾗIﾗﾉ ;ﾐS ﾏ;ヴﾆWS ;ゲ さCRITICAL “TEPざ ｷﾐ デｴW 
protocol section. Two additional paragraphs have been included in the discussion section of the revised 
manuscript discussing the critical steps, options for troubleshooting the technique and limitations of 
the technique.  
References: 
1. Please ensure that the references appear as the following: [Lastname, F.I., LastName, F.I., LastName, 
F.I. Article Title. Source. Volume (Issue), FirstPage に LastPage (YEAR).] For more than 6 authors, list 
only the first author then et al.  
Response: The references have been re-formatted according to the suggested style. 
 Table of Materials: 
1. Please reﾏﾗ┗W デヴ;SWﾏ;ヴﾆ ふゥぶ ;ﾐS ヴWｪｷゲデWヴWS ふイぶ ゲ┞ﾏHﾗﾉゲ aヴﾗﾏ デｴW T;HﾉW ﾗa M;デWヴｷ;ﾉゲく  
Response: The trademark and registered symbols have been removed from the revised Table of 
Materials. 
2. Please ensure the Table of Materials has information on all materials and equipment used, 
especially those mentioned in the Protocol.  







Well written article and described technique. 
 
Ln52 the issues with conventional in-vitro models should be referenced 
Response: Two references that describe the issues with conventional models have been added to the 
revised manuscript. 
1. Ersoy, S. C. et al (2017) Correcting a Fundamental Flaw in the Paradigm for Antimicrobial 
Susceptibility Testing. EBioMedicine. dx.doi.org/10.1016/j.ebiom.2017.05.026 
2. Kubicek-Sutherland, J. Z. et al. (2015) Host-dependent Induction of Transient Antibiotic 
Resistance: A Prelude to Treatment Failure. EBioMedicine. 
dx.doi.org/10.1016/j.ebiom.2015.08.012 
It would be good to estimate the number of in-vivo experiments conducted yearly to emphasise the 
need for reliable ex-vivo models  
Response: This is a great suggestion and the authors agree that the suggested comparison would 
emphasise the need for ex-vivo models. Unfortunately, the authors do not perform in-vivo experiments, 
and therefore are unable to provide an estimate of the number of in-vivo experiments one can conduct 
yearly. The authors estimate that the maximum number of ex-vivo corneas one researcher can process 
is 40 corneas per week, so one can process approximately 2000 corneas per year. This is a reasonable 
throughput. No change has been made in the revised manuscript concerning this suggestion. 
Ln70 what effect does the 2 hour delay from enucleation have. Are the pigs blanched or disinfected?  
Response: The pigs are neither blanched nor disinfected. The eyes are closed after the killing and the 
pigs are refrigerated. The 2 hour delay from enucleation is due to practical issues around staff 
availability and processing time in the abattoir and cannot be avoided. Based on the literature on 
enucleation of eyes from human cadaveric donors for transplantation, no adverse effect is expected 
during the 2 hour delay. For instance, according to Mohamed et al. 2016, human corneas removed 
within 6 to 10 hours from death can be used for tissue transplantation, provided the cadavers are 
refrigerated. 
Mohamed, A. et al. (2016) Outcome of transplanted donor corneas with more than 6 h of 
death-to-preservation time. Indian Journal of Ophthalmology. DOI: 10.4103/0301-
4738.194338 
Why the choice of glass for the moulds compared to a 3D printed design?  
Response: Glass was the preferred material due to practical reasons. The authors had ready 
accessibility to the services of a glass blower rather than a 3D printer. The authors therefore found 
securing glass moulds less time consuming and cost effective. Using glass as the material for moulds 
also meant that the moulds can be sterilised by autoclaving between use which minimised issues 
related to microbial contamination. 
Lu 118 indicate PA01 and PA14 are strains  
Response: The requested change has been made in the revised manuscript (Part 5 step 2). 
What is the thickness of the glass in Figure 1A.  
Response: The glass moulds were cut out of standard size laboratory tubes made of borosilicate glass. 
An additional sentence has been added to the figure legend to clarify this point. 
 
Could do with a control to show minimal/no CFU and ideally the CFU over several time points 
Response: Uninfected control cornea were always set up alongside each batch. Everytime, no colony 
forming units were recovered from uninfected controls. An additional step has been included in the 
protocol section (Part 6 step 9) of the revised manuscript to emphasise this point. An additional 
sentence has been added to the end of the figure legend to emphasise that no CFU were recovered 
from the uninfected controls. The authors have followed the progression of infection over several time 
points as suggested by the reviewer. However, this has not been included in this manuscript as it will 
be included in a forthcoming publication. Therefore, no change has been made regarding this 
suggestion in the revised manuscript. 
Reviewer #2: 
Manuscript Summary: 
The glass mould is a fairly innovative and elegant idea that can help standardise infection experiments 
to yield reproducible results. There are, however, some details that can be optimised to fully utilise 
the potential of this model. 
Major Concerns: 
1-You mentioned that the corneas swell up over the course of the experiments. In my experience, this 
can potentially skew some results, especially in studies where structural integrity is important such as 
studying biofilm formation. The cornea can increase significantly in thickness reaching well above 1000 
microns. This can also affect live confocal imaging studies if this model is to be used, as the resolution 
would be significantly affected by the thickened cornea with its relatively disorganised collagen fibres 
and inter-fibrillary spaces. Adding Dextran to culture medium may help mitigate those problems. 
Response: The authors agree with the reviewer that the addition of dextran will mitigate swelling of 
the corneas. The authors conducted an experiment to compare the CFU recovered after 24 hours of 
infection from dextran treated and untreated cornea. We observed no significant difference in the 
number of CFU recovered suggesting that addition of dextran did not affect infection of the cornea. 
Please see graph below. The authors note that it was difficult to filter sterilise dextran which resulted 
in a lot of corneas developing contamination. This is why addition of dextran is suggested in the original 
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2- The method of quantifying the infection dose seems to be crude, only approximating the number 
of CFU/15 ul used. If this model was to be used in infection experiments testing therapeutic agents for 
example, a more accurate quantification must be used to allow the measurement of the effect of a 
therapeutic agent, for example, or the growth pattern of bacteria. In step 10, you recommend diluting 
to 10-4 or 10-5, but it is not clear what such a recommendation is based on. If the initial infection dose 
is not accurately quantified, and verified by viable counting, such a dilution may yield very variable, 
even unexpected, results 
Response: The authors apologise for lack of clarity in the manuscript regarding the quantification of 
the infective dose. Every time the experiment was performed, the infective dose was verified by viable 
plate count to ensure that the target infective dose of 1 x 107 CFU per cornea was delivered to the 
cornea in the 15 uL used. Please see graph below. An additional step has been added to the revised 
manuscript (Part 7 step 12) to emphasise this.  
 
The recommended dilution in step 10, is to allow the recovery of sufficient CFU on the agar plate during 

















10-5 dilution is necessary after 24 hours incubation to recover at least 30 CFU per agar plate for viable 
plate count i.e. the minimum recommended CFU for reproducible viable plate count. The authors agree 
that when testing the effect of therapeutics the required dilution factor must be arrived at 
experimentally for reproducible results. An additional sentence has been added to part 7 step 11 to 
emphasise this point. 
 
3- In Part 6. Infecting the corneoscleral button: Step 3 is not very clear. You mentioned a sterile glass 
ring - is that the same as your proposed glass mould? How do you "seal the glass ring"? Do you pour 
some of the agar-containing DMEM between the mould and the cornea? This part needs more 
elaboration.  
Response: The authors have modified the wording of this step (Part 6 step 3) to improve clarity. The 
sealing of the glass ring is done by adding sufficient DMEM agar (1 mL) to fill the mould completely. 
The authors appreciate that this is difficult to get across and feel this is a crucial step, the clarity of 
which will be additionally aided by the video produced by the journal. The wording of part 6 step 4 has 
been modified to improve clarity. 
 
4- In step 6: You mentioned "bacterial culture", do you mean the infective solution? In my experience, 
100 microlitres of PBS can evaporate fairly quickly off the surface of the cornea over 24h, leaving a 
dry, distorted epithelial surface. This may affect the results of infection experiments carried out using 
this model, especially imaging studies, like scanning electron microscopy, for instance.  
Response: All incubation steps were carried out in a humidified incubator with relative humidity levels 
at 90%. The authors have not observed evaporation of the PBS within the timeframes of incubation 
reported in the manuscript. 
 
Minor Concerns: 
1- the use of antibiotics in the culture medium can affect bacterial growth, despite washing and 
maintaining in antibiotic-free media for 3 days. One way to ensure the lack of the undesirable effect 
of antibiotics is to observe the growth of bacteria (e.g. growth curve) in the supernatant from this 
antibiotic-free medium immediately before commencing the infection experiment. 
Response: The authors thank the reviewer for the suggestion, and for particularly stating this point as 
a minor concern. As the reviewer notes, the corneas placed in antibiotic-containing medium are 
washed multiple times in PBS before transferring the corneas to the antibiotic-free medium. There is 
typically a 24 hour incubation in antibiotic-free medium. There is a subsequent removal and 
replacement of the antibiotic-free medium and a further incubation for 48 hours before infection. The 
authors have performed an experiment in which CFU recovered per cornea after a 24 hour infection 
was enumerated and compared from cornea placed in antibiotic-free media for 24, 48 and 72 hours. 
Please see graph below. No significant difference was observed in the number of CFU recovered 
suggesting that antibiotics are reduced to negligible levels (if not completely eliminated) even after 24 
hours of incubation in antibiotic-free medium. Therefore, the authors believe that antibiotics used will 
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